In a previous article, this group described the principles involved in the development of bioengineered skin equivalents that held out much promise. This article has examined some of the uses of such products in treating venous ulcers, diabetic foot ulcers, and skin diseases leaving skin wounds. Data encouraging the use of such products in certain indications are available. The costs of using such products are also appreciated.
Falanga V. Classifications for wound bed preparation and stimulation of chronic wounds. Wound Repair Regen2000;8:347-352.
2.
Boschi E, Longoni BM, Romanelli M, Mosca F. Cutaneous tissue engineering and lower extremity wounds (Part 1). Int J Lower Extremity Wounds2004;3(2):80-86.
3.
Jimenez PA, Jimenez SE. Tissue and cellular approaches to wound repair. Am J Surg2004;187(Suppl. May):56S-64S.
4.
Jahoda CA, Reynolds AJ. Hair follicle dermal sheath cells: unsung participants in wound healing. Lancet2001;358:1445-1448.
5.
Eaglstein WH, Alvarez OM, Auletta M, et al.A composite skin substitute (Graftskin®) for surgical wounds: a clinical experience. Dermatol Surg1995;21:839-843.
6.
Mansbridge J, Liu K, Patch R, Symons K, Pinney E. Three-dimensional fibroblast culture implant for the treatment of diabetic foot ulcers: metabolic activity and therapeutic range. Tissue Eng1998;4:403-414.
7.
Phillips TJ, Dover JS. Leg ulcers. J Am Acad Dermatol1991;25:965-987.
8.
Bell E, Ehrlich HP, Buttle DJ, Nakatsuji T. Living tissue formed in vitro and accepted as skin-equivalent tissue of full thickness. Science1981;211:1052-1054.
9.
Leigh IM, Purkis PE, Navsaria HA, Phillips TJ. Treatment of chronic venous ulcers with sheets of cultured allogenic keratinocytes. Br J Dermatol1987;117:591-597.
10.
Sabolinski ML, Alvarez O, Auletta M, Mulder G, Parenteau NL. Cultured skin as a ‘smart material’ for healing wounds: experience in venous ulcers. Biomaterials1996;17:311-320.
11.
Falanga V, Margolis D, Alvarez O, et al.Rapid healing of venous ulcers and lack of clinical rejection with an allogenic cultured human skin equivalent. Arch Dermatol1998;134:293-300.
12.
Falanga V, Sabolinski M. A bilayered living skin construct (APLIGRAF®) accelerates complete closure of hard-to-heal venous ulcers. Wound Repair Regen1999;7:201-207.
13.
Milstone LM, Asgari MM, Schwartz PM. Growth factor expression, healing and structural characteristics of Graftskin (Apligraf®). Wounds2000;12(Suppl A):12A-19A.
14.
Omar AA, Mavor AID, Jones AM, Homer-Vanniasinkam S. Treatment of venous leg ulcers with Dermagraft®. Eur J Endovasc Surg2004;27:666-672.
15.
Tausche AK, Skaria M, Bohlen L, et al.An autologous epidermal equivalent tissue-engineered from follicular outer sheath keratinocytes is as effective as split-thickness skin autograft in recalcitrant vascular leg ulcers. Wound Repair Regen2003;11:248-252.
16.
Mostow EN, Haraway GD, Dalsing M, et al.Effectiveness of an extracellular matrix graft (OASIS Wound Matrix) in the treatment of chronic leg ulcers: a randomized clinical trial. J Vasc Surg2005;41:837-843.
17.
Lazarus GS, Cooper DM, Knighton DR, et al.Definitions and guidelines for assessment of wounds and evaluation of healing. Arch Dermatol1994;130(4):489-493.
18.
Brem H, Balledux J, Bloom T, Kerstein MD, Hollier L. Healing of diabetic foot ulcers and pressure ulcers with human skin equivalent: a new paradigm in wound healing. Arch Surg2000;135:627-634.
19.
Harding KG, Morris HL, Patel GK. Science, medicine and the future: healing chronic wounds. BMJ2002;324:160-163.
20.
Apelqvist J, Larsson J. What is the most effective way to reduce the incidence of amputation in the diabetic foot?Diabetes Metab Res Rev2000;16(Suppl 1):S75-S83.
21.
Boulton AJM. Clinical presentation and management of diabetic neuropathy and foot ulceration. Diabet Med1991;8:552-557.
22.
Reiber GE, Vileikyte L, Boyko EJ, et al.Causal pathways for incident lower-extremity ulcers in patients with diabetes from two settings. Diabetes Care1999;22:157-162.
23.
Gentzkow GD, Iwasaki SD, Hershon KS, et al.Use of Dermagraft, a cultural human dermis, to treat diabetic foot ulcers. Diabetes Care1996;19:350-354.
24.
Veves A, Falanga V, Armstrong DG, Sabolinski ML. Graftskin, a human skin equivalent, is effective in the management of noninfected neuropathic diabetic foot ulcers. A prospective randomized multicenter clinical trial. Diabetes Care2001;24:290-295.
25.
Caravaggi C, Faglia E, De Giglio R, et al.Effectiveness and safety of a non-removable fiberglass off-bearing cast versus a therapeutic shoe in the treatment of neuropathic foot ulcers. Diabetes Care2000;23:1746-1751.
26.
Armstrong DG, Ngyugen HC, Lavery LA, et al.Off-loading the diabetic foot wound: a randomized clinical trial. Diabetes Care2001;24:1019-1022.
27.
Piaggesi A, Viacava P, Rizzo L, et al.Semiquantitative analysis of the histopathological features of the neuropathic foot ulcer: effect of pressure relief. Diabetes Care2003;26:3123-3128.
28.
Caravaggi C, De Giglio R, Pritelli C, et al.HYAFF 11-based autologous dermal and epidermal grafts in the treatment of noninfected diabetic plantar and dorsal foot ulcers. A prospective, multicenter, controlled, randomised clinical trial. Diabetes Care2003;26:2853-2859.
29.
Piaggesi A, Baccetti F, Rizzo L, Romanelli M, Navalesi R, Benzi L. Sodium carboxyl-methyl-cellulose dressings in the management of deep ulcerations of diabetic foot. Diabet Med2001;18(4):320-324.
30.
Caputo GM, Cavanagh PR, Ulbrecht JS, Gibbons GW, Karchmer AW. Assessment and management of foot disease in patients with diabetes. N Engl J Med1994;331:854-860.
31.
Uccioli L. Clinical results related to the use of tissuetech autograft system in the treatment of diabetic foot ulceration. Wounds2003;15:279-288.
32.
Phillips TJ, Bigby M, Bercovitch L. Cultured allografts as an adjunct to the medical treatment of problematic leg ulcers. Arch Dermatol1991;127:799-801.
33.
De Imus G, Golomb C, Wilkel C, Tsoukas M, Nowak M, Falanga V. Accelerated healing of pyoderma gangrenosum treated with bioengineered skin and concomitant immunosuppression. J Am Acad Dermatol2001;144:61-66.
34.
Pennoyer JW, Susser WS, Chapman MS. Ulcers associated with polyarteritis nodosa treated with bioengineered human skin equivalent (Apligraf®). J Am Acad Dermatol2002;46:145.
35.
Drosou A, Kirsner RS, Kato T, et al.Use of a bioengineered skin equivalent for the management of difficult skin defects after pediatric multivisceral transplantation. J Am Acad Dermatol2005;52:854-858.
36.
Charles CA, Kato T, Tzakis AG, Miller BN, Kirsner RS. Use of a living dermal equivalent for a refractory abdominal defect after pediatric multivisceral transplantation. Dermatol Surg2004;30(9):1236-1240.
37.
Falabella AF, Schachner LA, Valencia IC, Eaglstein WH. The use of tissue-engineered skin (Apligraf) to treat a newborn with Epidermolysis bullosa. Arch Dermatol1999;135:1219-1222.
38.
Wollina U, Konrad H, Fischer T. Recessive epidermolysis bullosa dystrophicans (Hallopeau-Siemens): improvement of wound healing by autologous epidermal grafts on an esterified hyaluronic acid membrane. J Dermatol2001;28(4):217-220.
39.
Flores F, Eaglstein WH, Kirsner RS. Hydroxyurea-induced leg ulcers treated with Apligraf. Ann Intern Med2000;132:417.
